Entheon Biomedical (XCNQ:ENBI) Change In Payables And Accrued Expense : C$-0.10 Mil (TTM As of Feb. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical Change In Payables And Accrued Expense?

Entheon Biomedical's Change In Payables And Accrued Expense for the quarter that ended in Feb. 2024 was C$-0.03 Mil. It means Entheon Biomedical's Accounts Payable & Accrued Expense declined by C$0.03 Mil from Nov. 2023 to Feb. 2024 .

Entheon Biomedical's Change In Payables And Accrued Expense for the fiscal year that ended in Nov. 2023 was C$-0.07 Mil. It means Entheon Biomedical's Accounts Payable & Accrued Expense declined by C$0.07 Mil from Nov. 2022 to Nov. 2023 .

Entheon Biomedical Change In Payables And Accrued Expense Historical Data

The historical data trend for Entheon Biomedical's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical Change In Payables And Accrued Expense Chart

Entheon Biomedical Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Nov21

Nov22

Nov23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-0.06

0.01

-0.63

-0.07

Entheon Biomedical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-0.06	-0.05	0.05	-0.03

Entheon Biomedical Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.10 Mil.

Entheon Biomedical Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Entheon Biomedical's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Entheon Biomedical (XCNQ:ENBI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

ENTBF:USA 1XU1:Germany

Address

999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5

Website

https://www.entheonbiomedical.com

Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.

Executives

Brian Jahns

Senior Officer

Entheon Biomedical (XCNQ:ENBI) Headlines

No Headlines